MedTrace Logo

The Progressive Supranuclear Palsy Clinical Trial Platform

NCT07173803 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2026-04-27

No results posted yet for this study

Summary

The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.

Conditions

  • Progressive Supranuclear Palsy(PSP)

Interventions

BIOLOGICAL

AADvac1

Active immunotherapy

DRUG

LM11A-31

Small molecule

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Alzheimer's Therapeutic Research Institute

    collaborator OTHER

  • University of Southern California

    collaborator OTHER

  • Massachusetts General Hospital

    collaborator OTHER

  • University of California, San Diego

    collaborator OTHER

  • Alzheimer's Clinical Trials Consortium

    collaborator OTHER

  • Adam Boxer

    lead OTHER

Principal Investigators

  • Adam Boxer, MD, PhD · University of California, San Francisco

  • Irene Litvan, MD · University of California, San Diego

  • Julio Rojas-Martinez, MD, PhD · University of California, San Francisco

  • Anne-Marie Wills, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
41 Years
Max Age
86 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2030-09-28
Completion
2030-09-28
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07173803 on ClinicalTrials.gov